Related references
Note: Only part of the references are listed.Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Ola Landgren et al.
BLOOD (2009)
Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma
Mitsufumi Nishio et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment
VD Garcia et al.
TRANSPLANT INTERNATIONAL (2003)
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo:: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders
M Majewski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
